Acknowledgments
Nickel Melanoma, A., Cancer
SCHULTZ, CANCER
This study was funded in part by Bristol Myers Squibb, who provided nivolumab and ipilimumab, and the study drug talimogene laherparepvec was provided by Amgen. T.S. Nowicki was supported by NIH grant K08 CA241088. K.M. Campbell was supported by the Cancer Research Institute Irvington Postdoctoral Fellowship Program, the V Foundation Gil Nickel Melanoma Research Fellowship, and the Parker Institute for Cancer Immunotherapy and V Foundation Bridge Fellows Program. A. Ribas was supported by NIH/NCI grants R35 CA197633 and P01CA244118, the Parker Institute for Cancer Immunotherapy (PICI), the V Foundation Gil Nickel Melanoma Research Fellowship, the Ressler Family Fund, and Ken and Donna Schultz.
